Rakovina Therapeutics Granted DTC Eligibility to Expand U.S. Investor Access

Core Insights - Rakovina Therapeutics Inc. has achieved DTC eligibility, allowing its shares to be electronically cleared and settled, which enhances liquidity and market accessibility for U.S. investors [1][2][3] Group 1: DTC Eligibility Impact - DTC eligibility streamlines trading for U.S. investors, removing barriers and reducing costs and processing times [2][3] - This development is expected to increase Rakovina's visibility and accessibility to a broader base of institutional and retail investors [3] Group 2: Strategic Growth and Corporate Developments - The company is advancing its preclinical programs and exploring strategic partnerships in AI-enhanced diagnostics and oncology therapeutics [4] - Additional corporate developments are anticipated as the company continues to execute its strategic roadmap [4] Group 3: Company Overview - Rakovina Therapeutics focuses on developing innovative cancer treatments using AI technologies, specifically targeting DNA-damage response through its proprietary platforms [5][6] - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [6]